An inflammation-based prognostic index predicts survival advantage after transarterial chemoembolization in hepatocellular carcinoma

Translational Research

Volumn 160, Issue 2, 2012, Pages 146-152

  Pinato, David J ^a,b   Sharma, Rohini ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b UNIVERSITY OF EASTERN PIEDMONT   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CHEMOEMBOLIZATION; CLINICAL FEATURE; FEMALE; HISTOPATHOLOGY; HUMAN; INFLAMMATION; LIVER CELL CARCINOMA; LIVER FUNCTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL COUNT; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROGNOSIS; STATISTICAL ANALYSIS; TREATMENT RESPONSE;

EID: 84863973568     PISSN: 19315244     EISSN: 18781810     Source Type: Journal    
DOI: 10.1016/j.trsl.2012.01.011     Document Type: Article

References (44)

1. J.M. Llovet, and J. Bruix Novel advancements in the management of hepatocellular carcinoma in 2008 J Hepatol 48 Suppl 1 2008 S20 S37
2. J.M. Llovet, and J. Bruix Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival Hepatology 37 2003 429 442 (Pubitemid 36152543)
3. R. Lencioni Loco-regional treatment of hepatocellular carcinoma Hepatology 52 2010 762 773
4. M. Kudo, N. Izumi, and N. Kokudo Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version Dig Dis 29 2011 339 364
5. J.L. Raoul, B. Sangro, and A. Forner Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization Cancer Treat Rev 37 2011 212 220
6. J. Bruix, and M. Sherman Management of hepatocellular carcinoma Hepatology 42 2005 1208 1236 (Pubitemid 43112690)
7. C. Camma, F. Schepis, and A. Orlando Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials Radiology 224 2002 47 54 (Pubitemid 34680374)
8. L. Marelli, R. Stigliano, and C. Triantos Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies Cardiovasc Intervent Radiol 30 2007 6 25 (Pubitemid 44900485)
9. G. Cabibbo, C. Genco, and V. Di Marco Predicting survival in patients with hepatocellular carcinoma treated by transarterial chemoembolisation Aliment Pharmacol Ther 34 2011 196 204
10. M.R. Alison, L.J. Nicholson, and W.R. Lin Chronic inflammation and hepatocellular carcinoma Recent Results Cancer Res 185 2011 135 148
11. M.J. Proctor, D.S. Morrison, and D. Talwar An inflammation-based prognostic score (mGPS) predicts cancer survival independent of tumour site: a Glasgow Inflammation Outcome Study Br J Cancer 104 2011 726 734
12. B.B. Aggarwal, R.V. Vijayalekshmi, and B. Sung Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe Clin Cancer Res 15 2009 425 430
13. E. Van Cutsem, and J. Arends The causes and consequences of cancer-associated malnutrition Eur J Oncol Nurs 9 Suppl 2 2005 S51 S63
14. P.J. Vlachostergios, I. Gioulbasanis, and K. Kamposioras Baseline insulin-like growth factor-I plasma levels, systemic inflammation, weight loss and clinical outcome in metastatic non-small cell lung cancer patients Oncology 81 2011 113 118
15. R. Sharma, M. Zucknick, and R. London Systemic inflammatory response predicts prognosis in patients with advanced-stage colorectal cancer Clin Colorectal Cancer 7 2008 331 337
16. W. Chua, K.A. Charles, and V.E. Baracos Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer Br J Cancer 104 2011 1288 1295
17. S.C. Kao, N. Pavlakis, and R. Harvie High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy Clin Cancer Res 16 2010 5805 5813
18. W. Chua, S.J. Clarke, and K.A. Charles Systemic inflammation and prediction of chemotherapy outcomes in patients receiving docetaxel for advanced cancer Support Care Cancer 2011 Oct 11 [Epub ahead of print]
19. S.J. Clarke, W. Chua, and M. Moore Use of inflammatory markers to guide cancer treatment Clin Pharmacol Ther 90 2011 475 478
20. J.F. Seymour, M. Talpaz, and F. Cabanillas Serum interleukin-6 levels correlate with prognosis in diffuse large-cell lymphoma J Clin Oncol 13 1995 575 582
21. I. Ray-Coquard, C. Cropet, and M. Van Glabbeke Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas Cancer Res 69 2009 5383 5391
22. C.S. Roxburgh, J.M. Salmond, and P.G. Horgan The relationship between the local and systemic inflammatory responses and survival in patients undergoing curative surgery for colon and rectal cancers J Gastrointest Surg 13 2009 2011 2019
23. K.J. Halazun, M.A. Hardy, and A.A. Rana Negative impact of neutrophil-lymphocyte ratio on outcome after liver transplantation for hepatocellular carcinoma Ann Surg 250 2009 141 151
24. D. Gomez, S. Farid, and H.Z. Malik Preoperative neutrophil-to-lymphocyte ratio as a prognostic predictor after curative resection for hepatocellular carcinoma World J Surg 32 2008 1757 1762
25. Z.L. Huang, J. Luo, and M.S. Chen Blood neutrophil-to-lymphocyte ratio predicts survival in patients with unresectable hepatocellular carcinoma undergoing transarterial chemoembolization J Vasc Interv Radiol 22 2011 702 709
26. J. Bruix, M. Sherman, and J.M. Llovet Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver J Hepatol 35 2001 421 430 (Pubitemid 32844200)
27. M.H. Lee, S.U. Kim, and D.Y. Kim Early on-treatment predictions of clinical outcomes using AFP and DCP responses in patients with advanced hepatocellular carcinoma J Gastroenterol Hepatol 2011 Jul 28 [Epub ahead of print]
28. T. Yau, T.J. Yao, and P. Chan The significance of early alpha-fetoprotein level changes in predicting clinical and survival benefits in advanced hepatocellular carcinoma patients receiving sorafenib Oncologist 16 2011 1270 1279
29. J.M. Llovet, M.I. Real, and X. Montana Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial Lancet 359 2002 1734 1739 (Pubitemid 34607087)
30. J. Bruix, M. Sala, and J.M. Llovet Chemoembolization for hepatocellular carcinoma Gastroenterology 127 5 Suppl. 1 2004 S179 S188
31. R. Miraglia, G. Pietrosi, and L. Maruzzelli Predictive factors of tumor response to trans-catheter treatment in cirrhotic patients with hepatocellular carcinoma: a multivariate analysis of pre-treatment findings World J Gastroenterol 13 2007 6022 6026 (Pubitemid 350238269)
32. T.M. Chen, C.C. Lin, and P.T. Huang Neutrophil-to-lymphocyte ratio associated with mortality in early hepatocellular carcinoma patients after radiofrequency ablation J Gastroenterol Hepatol 2011 Sep 13 [Epub ahead of print]
33. M.J. Proctor, D.S. Morrison, and D. Talwar A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study Eur J Cancer 47 2011 2633 2641
34. C.S. Roxburgh, and D.C. McMillan Role of systemic inflammatory response in predicting survival in patients with primary operable cancer Future Oncol 6 2010 149 163
35. R. Sharma, J. Hook, and M. Kumar Evaluation of an inflammation-based prognostic score in patients with advanced ovarian cancer Eur J Cancer 44 2008 251 256
36. L.M. Forrest, D.C. McMillan, and C.S. McArdle Comparison of an inflammation-based prognostic score (GPS) with performance status (ECOG) in patients receiving platinum-based chemotherapy for inoperable non-small-cell lung cancer Br J Cancer 90 2004 1704 1706 (Pubitemid 38725637)
37. H.B. El-Serag, J.A. Marrero, and L. Rudolph Diagnosis and treatment of hepatocellular carcinoma Gastroenterology 134 2008 1752 1763 (Pubitemid 351615415)
38. C. Berasain, J. Castillo, and M.J. Perugorria Inflammation and liver cancer: new molecular links Ann N Y Acad Sci 1155 2009 206 221
39. D.M. Kuang, Q. Zhao, and Y. Wu Peritumoral neutrophils link inflammatory response to disease progression by fostering angiogenesis in hepatocellular carcinoma J Hepatol 54 2011 948 955
40. N. Kobayashi, N. Hiraoka, and W. Yamagami FOXP3+ regulatory T cells affect the development and progression of hepatocarcinogenesis Clin Cancer Res 13 2007 902 911 (Pubitemid 46340366)
41. Z.Q. Yang, Z.Y. Yang, and L.D. Zhang Increased liver-infiltrating CD8+FoxP3+ regulatory T cells are associated with tumor stage in hepatocellular carcinoma patients Hum Immunol 71 2010 1180 1186
42. Y. Wu, Q. Zhao, and C. Peng Neutrophils promote motility of cancer cells via a hyaluronan-mediated TLR4/PI3K activation loop J Pathol 225 2011 438 447
43. J. Meza-Junco, A.J. Montano-Loza, and D.M. Liu Locoregional radiological treatment for hepatocellular carcinoma; Which, when and how? Cancer Treat Rev 38 2012 54 62
44. R. Lencioni, X.P. Chen, and L. Dagher Treatment of intermediate/advanced hepatocellular carcinoma in the clinic: how can outcomes be improved? Oncologist 15 Suppl 4 2010 42 52